The Economic Information Daily reported on the 16th that Cullgen-B (02162) is currently up 11.1%, trading at HK$84.6, with approximately 1.22 million shares traded, involving a turnover of HK$102 million.
Cullgen announced that its product Conyda (spesolimab) generated revenue of approximately RMB 660 million in the first three quarters of 2026, representing a year-on-year increase of about 227%, primarily driven by genuine market demand and a significant increase in the number of accessible hospitals. Since January this year, the drug's three indications and two packaging types have been included in the National Reimbursement Drug List, and in July, it was further included in the Essential Medicines List of China, further enhancing its accessibility.
Meanwhile, the National Medical Products Administration recently approved spesolimab (brand name: Conyda) for a new indication in the treatment of moderate-to-severe atopic dermatitis in adolescents (aged 12 to under 18 years). Phase III clinical trials showed that the EASI-75 response rate at week 18 reached 73.9%, significantly superior to the placebo group.
Currently, the Hang Seng Index stands at 24,331, up 268 points or 1.1%, with turnover on the main board nearing HK$36.9 billion. The Hang Seng China Enterprises Index stands at 8,191, up 88 points or 1.1%. The Hang Seng Tech Index stands at 4,135, up 74 points or 1.8%. (nw)
Cullgen announced that its product Conyda (spesolimab) generated revenue of approximately RMB 660 million in the first three quarters of 2026, representing a year-on-year increase of about 227%, primarily driven by genuine market demand and a significant increase in the number of accessible hospitals. Since January this year, the drug's three indications and two packaging types have been included in the National Reimbursement Drug List, and in July, it was further included in the Essential Medicines List of China, further enhancing its accessibility.
Meanwhile, the National Medical Products Administration recently approved spesolimab (brand name: Conyda) for a new indication in the treatment of moderate-to-severe atopic dermatitis in adolescents (aged 12 to under 18 years). Phase III clinical trials showed that the EASI-75 response rate at week 18 reached 73.9%, significantly superior to the placebo group.
Currently, the Hang Seng Index stands at 24,331, up 268 points or 1.1%, with turnover on the main board nearing HK$36.9 billion. The Hang Seng China Enterprises Index stands at 8,191, up 88 points or 1.1%. The Hang Seng Tech Index stands at 4,135, up 74 points or 1.8%. (nw)
